Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Erlotinib

Erlotinib (Synonyms: NSC 718781)

Catalog No.GC10627

An EGFR tyrosine kinase inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

Erlotinib Chemical Structure

Cas No.: 183321-74-6

Size Price Stock Qty
10mM (in 1mL DMSO)
$41.00
In stock
1g
$38.00
In stock
5g
$138.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Product Documents

Quality Control & SDS

View current batch:

Protocol

Kinase experiment [1]:

Binding assays

The kinase reaction was performed in50 μl of 50 mM HEPES(pH 7.3), containing 125 mM NaCl, 24 mM MgCl2, 0.1 mM sodium orthovanadate, 20 μM ATP, 1.6 μg/ml EGF, and 15 ng of EGFR. The compound in DMSO was added to give a final DMSO concentration of 2.5%. Phosphorylation was initiated by addition of ATP and proceeded for 8 min at room temperature with constant shaking. The kinase reaction was terminated by aspiration of the reaction mixture and was washed 4 times with wash buffer. Phosphorylated POT was measured by 25 min of incubation with 50 μl per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mI in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Removed antibody by aspiration and washed the plate 4 times with wash buffer. The colonmetric signal was developed by addition of TMB Microwell Peroxidase Substrate, 50 μl per well, and stopped by the addition of 0.09 M sulfuric acid, 50 μ1 per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm.

Cell experiment [1-3]:

Cell lines

Human NSCLC cell lines H322, A549, H1650, and H1975 cells.

Preparation method

The solubility of this compound in DMSO is >19.7mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

2 μmol/L, 24h

Applications

Erlotinib alone induced G1-phase arrest in ~80% H322 cells. Erlotinib (2 μM) significantly inhibited growth of AsPC-1 and BxPC-3 pancreatic cells. Erlotinib potently inhibited EGFR activation in HNS human head and neck tumor cells, DiFi human colon cancer cells and MDA MB-468 human breast cancer cells. Erlotinib (1 μM) induced apoptosis in DiFi human colon cancer cells.

Animal experiment [4]:

Animal models

H460a and A549 tumor models

Dosage form

100 mg/kg

Application

Erlotinib (100 mg/kg) exhibited antitumor activity at the MTD in both the H460a and A549 tumor models.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Moyer J D, Barbacci E G, Iwata K K, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase[J]. Cancer research, 1997, 57(21): 4838-4848.

[2]. Li T, Ling Y H, Goldman I D, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non–small cell lung cancer cells[J]. Clinical Cancer Research, 2007, 13(11): 3413-3422.

[3]. Ali S, Banerjee S, Ahmad A, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3, 3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer[J]. Molecular cancer therapeutics, 2008, 7(6): 1708-1719.

[4]. Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models[J]. Anti-cancer drugs, 2004, 15(5): 503-512.

Background

Erlotinib (also known as NSC 718781 or CP 358,774) is a potent and orally-bioavailable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase that selectively and reversibly inhibits EGFR-associated intracellular autophosphorylation of tyrosine kinase. Erlotinib inhibits purified EGFR tyrosine kinase and EGFR autophosphorylation intact cells with 50% inhibition concentration IC50 values of 2 nmol/L and 20 nmol/L respectively. Erlotinib competes for the ATP-binding sits on the intracellular domain of EGFR resulting in the inhibition of downstream signaling pathway involved in angiogenesis, cell propagation and cell survival. Erlotinib concentration-dependently inhibits EGFR-mediated propagation signals transduction, displays prominent anti-tumor activity against neoplasms harboring EGFR expression and exhibits a tolerable toxicologic profile.

Reference

[1].Janine Smith. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clinical Therapeutics 2005; 27(10): 1513-1534

Chemical Properties

Cas No. 183321-74-6 SDF
Synonyms NSC 718781
Chemical Name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
Canonical SMILES COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
Formula C22H23N3O4 M.Wt 393.44
Solubility ≥ 19.65 mg/mL in DMSO, ≥ 30.27 mg/mL in EtOH with gentle warming Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.5417 mL 12.7084 mL 25.4168 mL
5 mM 0.5083 mL 2.5417 mL 5.0834 mL
10 mM 0.2542 mL 1.2708 mL 2.5417 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for Erlotinib

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Erlotinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.